Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Benzinga · 6d ago
U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.
Shares of Smith & Wesson Brands Inc (NASDAQ:SWBI) fell sharply in pre-market trading after the company reported worse-than-expected fourth-quarter EPS and sales.
Smith & Wesson Brands reported fourth-quarter revenue of $140.8 million, missing analyst estimates of $152.41 million, according to Benzinga Pro. The company reported adjusted earnings of 20 cents per share in the fourth quarter, missing estimates of 23 cents per share.
Smith & Wesson Brands shares dipped 12.6% to $9.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
- Regencell Bioscience Holdings Ltd (NASDAQ:RGC) shares fell 16.2% to $52.96 in pre-market trading after dipping over 18% on Wednesday.
- QuantaSing Group Ltd- ADR (NASDAQ:QSG) fell 12.1% to $11.86 in pre-market trading.
- Aptevo Therapeutics Inc (NASDAQ:APVO) fell 11.9% to $4.52 in pre-market trading. Aptevo Therapeutics shares jumped 82% on Wednesday after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.
- Capricor Therapeutics Inc (NASDAQ:CAPR) fell 7.4% to $11.04 in pre-market trading. Capricor Therapeutics recently announced Orphan Drug designation for Becker Muscular Dystrophy.
- Mesoblast Ltd (NASDAQ:MESO) fell 6.5% to $10.94 in pre-market trading.
- Diginex Limited (NASDAQ:DGNX) dropped 6.5% to $43.51 in pre-market trading.
- Himalaya Shipping Ltd. (NASDAQ:HSHP) declined 6.3% to $6.22 in pre-market trading.
- AIRO Group Holdings, Inc. (NASDAQ:AIRO) fell 5.3% to $24.88 in pre-market trading.
Now Read This:
Photo via Shutterstock
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.